drugset / Trial / NCT03813836
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Phase 2
Active not recruiting
63 enrolled
University College, London
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Timeline
- Start
- 2019-07-05
- Primary completion
- 2024-01-10
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |